Lopez-Soley, E.
Martinez-Heras, E.
Solana, E.
Solanes, A.
Radua, J.
Vivo, F.
Prados, F.
Sepulveda, M.
Cabrera-Maqueda, J. M.
Fonseca, E.
Blanco, Y.
Alba-Arbalat, S.
Martinez-Lapiscina, E. H.
Villoslada, P.
Saiz, A.
Llufriu, S.
Funding for this research was provided by:
University of Barcelona
Instituto de Salud Carlos III (CPII19/00009)
Fomento de la Investigación and European Regional Development Fund
National Institute for Health Research
Biomedical Research Centre initiative
Red Española de Esclerosis Múltiple (RD16/0015/0002, RD16/0015/0003, RD12/0032/0002, RD12/0060/01-02)
TEVA Spain
Fundación Merck Salud, Spain
Proyecto Societat Catalana Neurologia
Instituto Carlos III (ISCIII) and co-funded by the European Union (PI15/00587, PI18/01030, PI21/01189, PI15/00061, JR16/00006, MV17/00021, PI17/01228, RD16/0015/0003)
ECTRIMS Clinical Training Fellowship Programme
MS Innovation GMSI
Article History
Received: 31 August 2022
Accepted: 24 February 2023
First Online: 2 March 2023
Competing interests
: EM-H, AS, JR, FV, EF, SA-A have nothing to disclose; EL-S and ES received travel reimbursement from Sanofi and ECTRIMS; FP received a Guarantors of Brain fellowship 2017–2020; MS received speaker honoraria from Genzyme, Novartis and Biogen; JMC-M received speaker honoraria from Sanfi; Y.B. received speaking honoraria from Biogen, Novartis and Genzyme; EHM-L received travel support for international and national meetings from Roche and Sanofi-Genzyme, and honoraria for consultancies from Novartis, Roche and Sanofi before joining the European Medicines Agency, where she is currently employed (Human Medicines, since 16 April 2019); however, her contribution to this article is related to her activity at the Hospital Clinic Barcelona/IDIBAPS and therefore does not represent the views of the Agency or its Committees. She is a member of the International Multiple Sclerosis Visual System (IMSVISUAL) Consortium; PV is a shareholder and has received consultancy fees from Accure Therapeutics SL, Attune Neurosciences Inc, QMenta Inc, Spiral Therapeutix Inc, CLight Inc and NeuroPrex Inc, as well as having held grants from the Instituto de Salud Carlos III and the European Commissions; AS received consulting fees and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, TEVA, Novartis and Roche, Janssen and Horizon Therapeutics; SL received consulting fees and speaker honoraria from Biogen Idec, Novartis, TEVA, Genzyme, Sanofi and Merck.